Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. (NASDAQ:VERX) ahead of its first Investor Day as a public company on March 19. The analyst reiterated the Buy rating ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Nvidia (NVDA) CEO Jensen Huang took to the stage Tuesday afternoon to deliver his keynote speech at the chip giant's 2025 GTC event (GPU Technology Conference), where he previewed the company's ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Working within the covariant formalism, we construct a 3-string vertex for closed bosonic strings compactified on M × Î©, where M is a (26 - 2 d )-dimensional Minkowski space and Ω is a d -complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback